A report of two families with sarcosinaemia in Hong Kong and revisiting the pathogenetic potential of hypersarcosinaemia

Annals of the Academy of Medicine Singapore

Volumn 35, Issue 8, 2006, Pages 582-584

  Lee, Shing Yan ^a   Chan, Kwok Yin ^a   Chan, Albert Y W ^a   Lai, Chi Kong ^a  

^a PRINCESS MARGARET HOSPITAL   (Hong Kong)

Author keywords

Gas chromatography mass spectrometry; Hypersacosinaemia; Sarcosine; Sarcosine dehydrogenase

Indexed keywords

SARCOSINE; SARCOSINE DEHYDROGENASE;

ACIDURIA; ANAMNESIS; ARTICLE; ASIA; AUTISM; AUTOSOMAL RECESSIVE DISORDER; CASE REPORT; CHILD; CLINICAL FEATURE; ENZYME DEFICIENCY; FEMALE; FOLIC ACID DEFICIENCY; GAS CHROMATOGRAPHY; HONG KONG; HUMAN; HYPERSARCOSINAEMIA; MASS SPECTROMETRY; MENTAL DEFICIENCY; METABOLIC DISORDER; SARCOSINAEMIA; URINALYSIS;

EID: 33750594079     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Levy HL, Coulombe JT, Benjamin R. Massachusetts Metabolic Disorders Screening Programme: III. Sarcosinemia. Pediatrics 1984;74:509-13.
2. Kuhara T. Diagnosis and monitoring of inborn errors of metabolism using urease-pretreatment of urine, isotope dilution, and gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002;781:497-517.
3. Brunialti AL, Harding CO, Wolff JA, Guenet JL. The mouse mutation sarcosinemia (sar) maps to chromosome 2 in a region homologous to human 9q33-q34. Genomics 1996;36:182-4.
4. Scott CR. Sarcosinemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Basis of Inherited Disease. 8th ed. New York: McGraw-Hill, 2001:2057-64.
5. Gerritsen T, Waisman HA. Hypersarcosinemia: an inborn error of metabolism. N Engl J Med 1966;275:66-9.
6. De Braekeleer M. Hereditary disorders in Saguenay-Lac-St-Jean (Quebec, Canada). Hum Hered 1991;41:141-6.
7. Harding CO, Williams P, Pflanzer DM, Colwell RE, Lyne PW, Wolff JA. Sar: a genetic mouse model for human sarcosinemia generated by ethylnitrosourea mutagenesis. Proc Natl Acad Sci U S A 1992;89: 2644-8.
8. Meissner T, Mayatepek E. Sarcosinaemia in a patient with severe progressive neurological damage and hypertrophic cardiomyopathy. J Inherit Metab Dis 1997;20:717-8.
9. Martina M, Gorfinkel Y, Halman S, Lowe JA, Periyalwar P, Schmidt CJ, et al. Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels. J Physiol 2004;557:489-500.
10. Bhutta AT, Anand KJ. Vulnerability of the developing brain. Neuronal mechanisms. Clin Perinatol 2002;29:357-72.
11. Coyle JT, Tsai G, Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann N Y Acad Sci 2003;1003:318-27.
12. Ballard TM, Pauly-Evers M, Higgins GA, Ouagazzal AM, Mutel V, Borroni E, et al. Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity. J Neurosci 2002;22: 6713-23.